Sci-fi to Sci-fact - Market Opportunities for Point of Care
HBS Consulting
February 1, 2002 120 Pages - SKU: HBSC888594
|
|
|
This report explores the
potential market size and the opportunities
arising in the area of genetic point of care testing.
It reviews the regulatory environment for genetic
testing in the US, the UK, France, Germany, Italy
and Japan, outlines opportunities and strategies
for market penetration, and wraps up with
highlights of the major companies active in
genetics, diagnostics and point of care testing.
Weaving together the market forces with the
strengths and shortcomings of the companies,
the report provides functional insight into the
opportunities for revenue generation in this field,
insight that will assist companies striving to
achieve the highest return on their diagnostics
investments.
|
1. Executive Summary
2. Introduction
- 2.1 Areas covered by this report
- 2.2 Report’s intended audience
3. Technology
- 3.1 The field of human genetics
- 3.1.1 What is genetic testing?
- 3.1.2 Core genetics for DNA testing
- 3.1.3 Genetic disorders
- 3.1.4 Oncogenes
- 3.2 Biochip technology
- 3.2.1 Microarrays
- 3.2.2 Microfluidics & lab chips
- 3.2.3 Integrated chips
- 3.2.4 Signal amplification
- 3.2.5 Nanotechnology
- 3.3 DNA-based diagnostic testing technology
- 3.3.1 Molecular probe (DNA) assays
- 3.3.2 PCR technology
- 3.4 From central laboratory to POC and POL
- 3.4.1 POC data management: the current lack of connectivity
4. Market analysis by region
- 4.1 The DNA POC market overall
- 4.2 USA
- 4.2.1 Healthcare expenditure on patient testing
- 4.2.2 Ethics, genetic testing and insurance
- 4.2.3 Implications for DNA POC testing
- 4.3 Europe overall
- 4.4 United Kingdom
- 4.4.1 Healthcare expenditure on patient testing
- 4.4.2 Ethics, genetic testing and insurance
- 4.4.3 Implications for DNA POC testing
- 4.5 France
- 4.5.1 Healthcare expenditure on patient testing
- 4.5.2 Ethics, genetic testing and insurance
- 4.5.3 Implications for DNA POC testing
- 4.6 Germany
- 4.6.1 Healthcare expenditure on patient testing
- 4.6.2 Ethics, genetic testing and insurance
- 4.6.3 Implications for DNA POC testing
- 4.7 Italy
- 4.7.1 Healthcare expenditure on patient testing
- 4.7.2 Ethics, genetic testing and insurance
- 4.7.3 Implications for DNA POC testing
- 4.8 Japan
- 4.8.1 Healthcare expenditure on patient testing
- 4.8.2 Ethics, genetic testing and insurance
- 4.8.3 Implications for DNA POC testing
- 4.9 The situation in developing nations
5. Market analysis by application
- 5.1 The major testing areas
- 5.1.1 Infectious disease testing
- 5.1.2 Fetal and newborn screening
- 5.1.3 Cancer
- 5.2 Is there a limit?
6. Market Analysis by End-Users of Testing
- 6.1 Hospitals
- 6.2 General and specialty laboratories
- 6.3 Physician office laboratory
- 6.4 Ambulatory care clinics/home testing
- 6.5 Other uses
7. Drivers, Restraints & Issues
- 7.1 Market drivers
- 7.1.1 Growing emphasis on near patient testing
- 7.1.2 Potential cost savings
- 7.1.3 Patient and physician demand
- 7.2 Market restraints
- 7.2.1 Cost
- 7.2.2 Reliability
- 7.2.3 Changes in the regulatory environments
- 7.2.4 Resistance from labs and pathologists
- 7.3 Issues
- 7.3.1 Ethics
- 7.3.2 Intellectual property
- 7.3.3 Public education and acceptance of genetic testing
8. Strategies and Opportunities
- 8.1 Marketing
- 8.1.1 Pricing
- 8.1.2 Channels of distribution
- 8.1.3 Sales strategies
- 8.2 Strategic alliances, mergers and acquisitions
- 8.2.1 The interplay of diagnostics and drug discovery
- 8.2.2 Biotechnology meets diagnostic device and
- pharmaceutical companies
- 8.3 Developed world opportunities
- 8.4 Developing world opportunities
9. Company Highlights
- 9.1 Aclara BioSciences Inc.
- 9.2 Agilent Technologies
- 9.3 Bayer Diagnostics
- 9.4 Beckman Coulter, Inc.
- 9.5 BioForce, Inc.
- 9.6 bioMérieux SA
- 9.7 Biosite Diagnostics, Inc.
- 9.8 Careside
- 9.9 Cepheid
- 9.10 Clinical Micro Sensors Inc.
- 9.11 Dade Behring
- 9.12 DiGene Corporation
- 9.13 Hyseq Inc.
- 9.14 Millennium Pharmaceuticals
- 9.15 Myriad Genetics Inc.
- 9.16 Nanogen
- 9.17 Orchid Biosciences
- 9.18 Qiagen
- 9.19 Roche Diagnostics
- 9.20 Third Wave Technologies Inc.
- 9.21 Visible Genetics Inc.
10. Appendices
- 10.1 Table 8: A list of manufacturers of microarrays,
- microfluidics and related equipment.
- 10.2 Consortia
- 10.3 Government organizations & useful addresses
- 10.4 Terms & abbreviations
- 10.5 Bibliography
Share this report
Other tasks Related Markets Point-of-Care Reports- 2012 Overview of the Laboratory and POC Hemostasis Diagnostic Markets: Facilities, Test Volumes, Sales Forecasts, and Key Player Market Shares
- 2012 World Hospital and Point-of-Care Coagulation Testing Market Outlook: Facilities, Test Volumes, Sales Forecasts, and Key Player Market Shares
- Point-of-Care Diagnostics - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
- The 2012 Hematology and Flow Cytometry Instrumentation Review: Operating Characteristics, Features and Selling PricesOf 60 High-, Medium-, and Low-Volume/POC Analyzers
- The 2012 Global Overview of the Laboratory and POC Coagulation Testing Markets: Facilities, Test Volumes, Sales Forecasts, and Key Player Market Shares
Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|